Seloken ZOC Forðatafla 95 mg Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

seloken zoc forðatafla 95 mg

recordati ireland limited* - metoprololum súkkínat - forðatafla - 95 mg

Seloken ZOC Forðatafla 47,5 mg Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

seloken zoc forðatafla 47,5 mg

recordati ireland limited* - metoprololum súkkínat - forðatafla - 47,5 mg

Seloken ZOC Forðatafla 23,75 mg Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

seloken zoc forðatafla 23,75 mg

recordati ireland limited* - metoprololum súkkínat - forðatafla - 23,75 mg

Seloken ZOC Forðatafla 190 mg Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

seloken zoc forðatafla 190 mg

recordati ireland limited* - metoprololum súkkínat - forðatafla - 190 mg

Namuscla Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

namuscla

lupin europe gmbh - mexiletine hydrochloride - myotonic kvilla - hjarta meðferð - namuscla er ætlað fyrir einkennum meðferð vöðvaherping í fullorðinn sjúklinga með ekki-dystrophic myotonic kvilla.

Veltassa Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

veltassa

vifor fresenius medical care renal pharma france - kalsíumhýdrat sorbítak - blóðkalíumlækkun - lyf til meðferð kalíum og blóðfosfathækkun - veltassa er ætlað til meðferðar við blóðkalíumhækkun hjá fullorðnum.

Xtandi Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

xtandi

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.